Arca
Skip to content
Tools
Tools

CD79B: B-cell antigen receptor complex-associated protein beta chain

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD79B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody-drug conjugate

Approved1

  • Polatuzumab vedotin

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        Polatuzumab vedotinApprovedRocheAntibody-drug conjugateBinding agentB-cell antigen receptor complex-associated protein beta chain binding agent83—

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Polatuzumab vedotinPhase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC2026-11-05
        Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaPolatuzumab vedotinPhase 2Not yet recruitingM.D. Anderson Cancer Center2026-11-05
        Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialPolatuzumab vedotinPhase 2Not yet recruitingUniversity of Washington2026-11-02
        Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyPolatuzumab vedotinPhase 4RecruitingThe First Hospital of Jilin University2026-11-02
        A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Polatuzumab vedotinPhase 3Not yet recruitingAstraZeneca2026-11-02
        Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasPolatuzumab vedotinPhase 2RecruitingNational Research Center for Hematology, Russia2026-10-20
        Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS InvolvementPolatuzumab vedotinPhase 2Not yet recruitingPengpeng Xu2026-09-10
        Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCLPolatuzumab vedotinNot applicableRecruitingThe First Affiliated Hospital of Xiamen University2026-08-21

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Isolated agammaglobulinemia
        0.64
        Autosomal agammaglobulinemia
        0.47
        Agammaglobulinemia
        0.47
        Abnormality of the skeletal system
        0.46
        B-cell non-Hodgkin lymphoma
        0.45
        Neoplasm
        0.41
        Diffuse large B-cell lymphoma of the central nervous system
        0.39
        Primary central nervous system lymphoma
        0.38
        Breast diffuse large B-cell lymphoma
        0.37
        Lymphoid neoplasm
        0.37
        Hemangioblastoma
        0.37

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712852, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P40259, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.